What is Axonics?
Founded in 2012, Axonics Modulation Technologies is at the forefront of developing novel implantable neuromodulation technology. The company's focus is on addressing several critical clinical indications through its advanced implantable devices. Axonics is strategically positioned within the burgeoning medtech industry, aiming to provide sophisticated solutions for patients requiring neuromodulation therapies. The company's commitment to innovation and its significant capital backing indicate a strong trajectory for growth and market penetration.
How much funding has Axonics raised?
Axonics has raised a total of $251.7M across 5 funding rounds:
Series A
$32.6M
Series B
$38.5M
Series C
$20.5M
Series D
$40.1M
Stock Offering
$120M
Series A (2014): $32.6M with participation from Neomed Management, Legend Capital, and Edmond de Rothschild Investment Partners (EdRIP)
Series B (2015): $38.5M led by The Alfred E. Mann Foundation, Edmond de Rothschild Investment Partners, Neomed Management, Legend Capital, Cormorant Asset Management, Advent Life Sciences, and Andera Partners
Series C (2017): $20.5M supported by CICA, Inc, Gilde Healthcare, and Cormorant Asset Management
Series D (2018): $40.1M featuring Gilde Healthcare, Silicon Valley Bank, and Longitude Capital
Stock Issuance/Offering (2018): $120M, investors not publicly disclosed
Key Investors in Axonics
Neomed Management
NeoMed Management is an international venture capital investment firm exclusively focused on the healthcare industry, investing in emerging companies with outstanding growth prospects in medical devices and diagnostics.
Gilde Healthcare
Gilde Healthcare is a specialized investment firm managing funds across venture & growth, private equity in healthcare, and climate solutions, focusing on businesses that enable better care at lower costs.
Cormorant Asset Management
Cormorant Asset Management is a prominent life sciences investment firm providing financial resources to innovative publicly traded and private companies in biotech and allied sectors.
What's next for Axonics?
The recent major strategic investment in Axonics signals a pivotal phase for the company, likely enabling accelerated product development, expanded clinical trials, and broader market commercialization efforts. This infusion of capital is expected to fuel the scaling of operations and further solidify Axonics' position in the competitive neuromodulation landscape. The company's ongoing pursuit of technological advancements in implantable devices suggests a future focused on enhancing patient outcomes and capturing significant market share within the healthcare technology sector.
See full Axonics company page
